Progesterone (Research)


Endogenous progestogen / PR agonist

The principal endogenous progestogen; a progesterone receptor agonist with luteal phase, gestational, and neurosteroid functions.

Abstract

Progesterone (pregn-4-ene-3,20-dione; CAS 57-83-0; molecular formula C21H30O2; molecular weight 314.46) is the principal endogenous progestogen, biosynthesized from cholesterol via pregnenolone in the corpus luteum, adrenal cortex, and (during pregnancy) placenta. The compound is a high-affinity progesterone receptor (PR) agonist with secondary effects at the glucocorticoid receptor (mineralocorticoid antagonism contributing to natriuretic effects) and at GABA-A receptors (the pregnanolone metabolite is a positive allosteric modulator producing sedation). Approved indications: menopausal hormone therapy (combined with estrogen for endometrial protection in women with intact uterus), assisted reproductive technology luteal support, secondary amenorrhea, and prevention of preterm birth (intramuscular formulation). Oral micronized progesterone (Prometrium) is highly subject to first-pass metabolism producing the sedating allopregnanolone metabolite; vaginal and transdermal forms produce more direct PR effects with less sedation. Plasma half-life is short (5 to 20 minutes for parent; metabolites variable). Used as the canonical PR agonist in research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph